skip to Main Content

References

3C Patch® will be the new name for LeucoPatch during 2019

Much of the clinical evidence for the 3C Patch® has been collected under the name LeucoPatch. Scientific evidence is a key element of the product´s development.

3C Patch® Publications

1. Game F., Jeffcoate W., Tarnow L., Jacobsen JL., Whitham DJ., Harrison EF., Ellender SJ., Fitzsimmons D., Löndahl M., LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked randomized controlled trial. www.thelancet.com/diabetes-endocrinology. Published online September 19, 2018 http://dx.doi.org/10.1016/S2213-8587(18)300240

2. Löndahl, M., Tarnow, L., Karlsmark, T., Lundquist, R., Nielsen, A. M., Michelsen, M., Jørgensen, B. (2015). Use of an autologous leucocyte and platelet rich fibrin patch on hard-to-heal DFUs: a pilot study. Journal of Wound Care, 24(4), 172–8.

3. Jørgensen, B., Karlsmark, T., Vogensen, H., Haase, L., & Lundquist, R. (2011). A pilot study to evaluate the safety and clinical performance of Leucopatch, an autologous, additive-free, platelet-rich fibrin for the treatment of recalcitrant chronic wounds. The International Journal of Lower Extremity Wounds, 10(4), 218–23

4. Lundquist, R., Holmstrøm, K., Clausen, C., Jørgensen, B., & Karlsmark, T. (2013). Characteristics of an autologous leukocyte and platelet-rich fibrin patch intended for the treatment of recalcitrant wounds. Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society, 21(1), 66–76.

5. Piaggesi A, Läuchli S, Bassetto F, et al. EWMA document: advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies. J Wound Care, 2018; 27(6)Suppl 6.

6. Thomsen, K., Trøstrup, H., Christophersen, L., Lundquist, R., Høiby, N., & Moser, C. (2016). The phagocytic fitness of leucopatches may impact the healing of chronic wounds. Clinical and Experimental Immunology, 184(3), 368–377.

7. Lundquist, R. (2016). Autologous cell-rich biomaterial (LeucoPatch) in the treatment of diabetic foot ulcers. Book chapter, Wound Healing Biomaterials Vol. 1 Ed. Ågren, M.

8. Game, F., Jeffcoate, W., Tarnow, L., Day, F., Fitzsimmons, D., & Jacobsen, J. (2017). The LeucoPatch® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial. Trials, 18(1).

3C Patch® Presentations

9. Löndahl, M., Jørgensen, B., Tarnow, L., Nielsen, A. M., Michelsen, M., Nilsson, A,, Mariusz Zakrzewski, M., Karlsmark, T. LeucoPatch™ seems to improve healing of diabetic foot ulcers – outcome from an open multicenter clinical study.DFSG Meeting, Potsdam, 2012.

10. Jørgensen, B., Löndahl, M., Tarnow, L., Nielsen, A. M., Michelsen, M., Nilsson, A,, Mariusz Zakrzewski, M., Karlsmark, T. Treatment Of Hard-To-Heal Diabetic Foot Ulcers With A Leucocyte And Platelet-Rich Fibrin Patch – A Prospective Scandinavian Multicenter Study. EWMA Meeting, 2013.

11. Van Acker. K. LeucoPatch®, a new approach to treat diabetic foot ulcers. Pisa Diabetic Foot Ulcer Course, Pisa, 2015.

12. Thomsen, K. LeucoPatch Anti-Bacterial Properties. ETRS, Copenhagen, 2015.

13. Fagher, K. LeucoPatchTM – Clinical Experience. ETRS, Copenhagen, 2015.

14. Jeffcoate, W. Leucopatch – The Definitive Trial. ETRS, Copenhagen, 2015.

15. Lundquist R. The unique adaptability of living immune cells in wound care is supported by comparing an autologous platelet and leucocyte rich fibrin patch with a dehydrated human amnion/chorion membrane allograft. Innovation in Wound Healing, Miami 2016.

3C Patch® Posters

16. Karlsmark, T., Lundquist, R., Vogensen, H., Haase, L. and Jørgensen, B. In vitro characterization of an autologous platelet and leukocyte rich fibrin and its clinical use in the treatment of chronic wounds. Poster EWMA Meeting 2012.

17. Löndahl, M., Jørgensen, B., Tarnow, L., Nielsen, A. M., & Michelsen, M. (2012). LeucoPatch seems to improve healing of diabetic foot ulcers – outcome from an open multicenter clinical study. Poster Diabetic Foot Study Groups 10th Annual Meeting. Potsdam; 2012.

18. Löndahl, M., Larsson, G., Elgzyri, T., Asmundsson, Å., Dupros, I., Ley, M., & Katzman, P. (2013). Treatment of hard-to-heal diabetic foot ulcers probing to bone with an autologous Leucocyte and platelet-rich fibrin patch. Poster EWMA meeting 2013.

19. Katzman, P., Fagher, K., Lundquist, R., & Löndahl, M.. Treatment Of Hard-to-heal Diabetic Foot Ulcers Probing To Bone With LeucopatchTM, A Leukocytes And Platelet Rich Fibrin Patch. Poster Abstract (A–4819) 74th ADA Meeting 2014, San Francisco, 2014.

20. Fagher, K., Katzman, P., Asmundsson, Å., Ley, M. R., Larsson, G., Ahlberg, M. Löndahl, M. A leukocytes and platelet rich fibrin patch as a novel treatment of malleoli ulcers in pa8ents with diabetes. POSTER ISDF. Den Haag, 2015.

21. Buyssens, A., A Moerck, AW,, Perceaux, D., Coessens, V., Van Acker, K. Case report: a patient with silent osteomyelitis receiving chemotherapy. A fully autologous growth factor dressing seems to be an option. Poster ISDF, Den Haag, 2015.

22. Thomsen, K., Trøstrup, H., Christophersen, L., Lundquist, R., Høiby, N., & Moser, C. Maintained Burst And Phagocytic Competence In Leucopatches May Terminate Bacterial Biofilms In Chronic Wounds. Poster American Society for Microbiology 115th General Meeting, New Orleans, 2015.

23. Thomsen, K., Trøstrup, H., Christophersen, L., Lundquist, R., Høiby, N., & Moser, C. Maintained Burst and Phagocytosis Effects of Leucopatches May Terminate Bacterial Biofilms in Chronic Wounds. Abstract ETRS, Copenhagen, 2015.

24. Löndahl, M., Katzman, P., Asmundsson, Å., Ley, M. R., Larsson, G., Ahlberg, M., Fagher, K. Treatment with a Leukocytes and Platelet Rich Fibrin Patch of Recalcitrant Malleoli Ulcers in Patients with Diabetes. Poster (CS-065) SAWC, Las Vegas, 2015.

25. Lundquist, R., Jørgensen, B., Fagher, K. and Löndahl, M. 3C Patch™ – an adaptive triple layered autologous platelet and leukocyte rich fibrin patch and its clinical use in the treatment of hard-to-heal diabetic foot ulcers.
Poster Innovations in Wound Healing, Miami, 2015.

26. Lundquist, R., Jørgensen, B., Karlsmark, T., Fagher, K. and Löndahl, M. 3C Patch™ – an adaptive triple layered autologous patch and its clinical use on hard-to-heal diabetic foot ulcers. Poster World Union of Wound Healing Societies, Florence, 2016.

27. Schmidt, J. The unique adaptability of living immune cells in wound care is supported by comparing an autologous platelet and leucocyte rich fibrin patch with a dehydrated human amnion/chorion membrane allograft. Poster Innovation in Wound Healing, Miami 2016.

28. Schmidt, J. Immunological perspectives of LeucoPatch treatment of Diabetic Foot Ulcers, DFSG Porto September 2017

29. Game F., Jeffcoate W., Tarnow L., Jacobsen JL., Whitham DJ., Harrison EF., Ellender SJ., Fitzsimmons D., Löndahl M., The LeucoPatch System In The Management of Hard-to-Heal Diabetic Foot Ulcers: A Multicentre, Multinational, Observer-blinded, Randomised Controlled Trial. American Diabetes Association (ADA): Florida: June 2018 P638

Guideline references

30. Steed DL, Attinger C, Colaizzi T, Crossland M, Franz M, Harkless L, Johnson A, Moosa H, Robson M, Serena T. Sheehan P, Veves A, Wiersma-Bryant L., Guidelines for the Treatment of diabetic ulcers. Wound Repair Regen. 2006; 14(6): 680-692.

Other references used on this site

31. Serra R, Grande R, Butrico L, Rossi A, Senttimio UF, Caroleo B, Amato B, Gallelli L, de Franciscis S,. Chronic Wound Infections: the role of Pseudonomas aeruginosa and Staphylococcus aureus. Expert Rev Anti Infec Ther. 2015, 13 (5): 605-13.

32. Falanga, V. (2005). Wound healing and its impairment in the diabetic foot. Lancet, 366(9498), 1736–43.

33. Boulton AJ., Vileikyte L., Ragnarson-Tennvall G., Apelqvest J., The global burden of diabetic foot disease. Lancet 2005; 366;1719-24.

34 Prompers L., Huijberts M., Apelqvist J., Jude E., Piagessi A., Bakker K., et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study, Diabetologia 2007;50;18-25.

35. Beckman J., Creager M., Libby P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 20002;287:2570-81.

36. Braverman IM. The cutaneous microcirculation.J Invest Dermatol Symp Proc 2000;5:3-9.

37. Rendell MS., Milliken BK., Finnegan MF., Finney DA., Healy JC., The skin blood flow response in wound healing . Microvasc Res 1997; 53 : 222-34.

38. Aller MA., Arias JI., Arraez-Aybar LA., Gilsanz C., Arias J., Wound healing reaction: a switch from gestation to senescence. World J Exp Med 2014; 4:16-26.

39. Mosser DM., Edwards JP., Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8;958-69.

40. Sun PC., Kuo CD., Chi LY., Lin HD., Wei SH., Chen CS., Microcirculatory vasomotor changes are associated with severity of peripheral neuropathy in patients with type 2 diabetes. Diab Vasc Dis Res 2013; 10:270-6.

41. Galkowska H., Wojewodzka U., Olszewski WL., Low recruitment of immune cells with increased expression of endothelial adhesion molecules in margins of the chronic diabetic foot ulcer. Wound Repair Regen 2005; 13:248-54.

42. Jörneskog G., Why critical limb ischemia criteria are not applicable to diabetic foot and what the consequences ar. Scand J Surg 2012;101: 114-8.

43. Pradhan L., Nabzdyk C., Andersen ND., LoGerfo FW., Veves A., Inflammation and neuropeptides:the connection in diabetic wound healing . Expert Rev Mol Med 2009;11;e2.

44. McInnes AD., Diabetic foot disease in the United Kingdom: about time to put feet first. Foot Ankle Res 2012;5:26.

45. The International Working Group on the Diabetic Foot. www.iwgdfguidance.org

Back To Top